Skip to main content
OpenTrials
Completed

NCT Number: NCT03161145

A Study to Observe the Treatment Patterns and Outcomes of Patients in Japan With Kidney Cancer That is Unable to be Removed by Surgery or That Has Spread

A medical review chart study in Japan to describe the treatment patterns and outcomes of patients with kidney cancer that is unable to be removed by surgery or that has spread. The clinical data is to be abstracted using electronic data capture (eDC) from patient medical records in Japan.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Renal Cell Carcinoma Adenocarcinoma Carcinoma Carcinoma, Renal Cell Female Urogenital Diseases Female Urogenital Diseases and Pregnancy Complications Kidney Diseases Kidney Neoplasms Male Urogenital Diseases Neoplasms Neoplasms by Histologic Type Neoplasms by Site Neoplasms, Glandular and Epithelial Urogenital Diseases Urogenital Neoplasms Urologic Diseases Urologic Neoplasms

Age range

20 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Local Institution

Tokyo, 1070052, Japan

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

For more information regarding Bristol-Myers Squibb Clinical Trial participation, please visit www.BMSStudyConnect.com

Inclusion criteria

  • Adults 20 years and older at the time of initial diagnosis of mRCC
  • Alive or deceased as of the date of data collection
  • Diagnosis of mRCC between 01-Jan-2012 and 31-Aug-2015

Exclusion criteria

  • Previously and/or currently enrolled in RCC clinical trials
  • Patients have primary cancer other than renal cell cancer

Treatment and study plan

Primary outcomes

  1. Treatment patterns

    Time frame: Approximately 5 years

    measured by retrospective data collection of treatment regimen and duration (including rate of permanent and temporary discontinuation)

  2. Overall survival

    Time frame: Approximately 2 years

    measured by data collection in years

  3. Reason for terminating or switching treatment

    Time frame: Approximately 5 years

    measured by data collection information available in retrospective analysis, if disclosed

  4. Adverse Events

    Time frame: Approximately 5 years

    measured by data collection

Sponsors and collaborators

Lead sponsor

Bristol-Myers Squibb

Industry

Collaborators

  • Ono Pharmaceutical Co., Ltd.

Registry information

Official study title

Treatment Patterns and Outcomes in Unresectable or Metastatic Renal Cell Carcinoma (mRCC) Patients in Japan

Important dates

Study start
2016
Primary completion
2017
Study completion
2017
First posted
May 19, 2017
Registry last updated
Oct 3, 2017

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.